Indication

Systemic dermatomyositis

Systemic dermatomyositis is a rare, immune-mediated idiopathic inflammatory myopathy characterized by widespread microvascular injury and multisystem involvement that affects both children and adults. Read more about Systemic dermatomyositis

340 drugs 164 manufacturers

Advertisement

Drugs that treat it

Common Systemic dermatomyositis therapies.

Showing 172–180 of 340 drugs

PREDNISOLONE

GLUCOCORTICOSTEROIDS·TRICHINOSIS·+59
PHARMACEU ASSOC

PREDNISONE

GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
Mylan Pharmaceuticals

DEXAMETHASONE

GLUCOCORTICOSTEROIDS·DISSEMINATED TUBERCULOSIS·+61
Major Pharamceuticals

METHYLPREDNISOLONE

GLUCOCORTICOSTEROIDS·DISSEMINATED TUBERCULOSIS·+55
Major Pharamceuticals

PREDNISONE

GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
Major Pharamceuticals

PREDNISONE

GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
GSK Consumer Healthcare

PREDNISONE

GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
BLENHEIM PHARMA
Filter & compare in the drug finder →Opens the drug finder with Systemic dermatomyositis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Systemic dermatomyositis.

Systemic dermatomyositis is a rare, immune-mediated idiopathic inflammatory myopathy characterized by widespread microvascular injury and multisystem involvement that affects both children and adults.

It classically manifests with hallmark cutaneous findings—such as a heliotrope rash and Gottron papules—paired with symmetric proximal muscle weakness and inflammatory myositis.

Beyond skeletal muscle and skin, the systemic disease frequently involves the pulmonary, gastrointestinal, and cardiovascular systems, presenting with complications such as interstitial lung disease, esophageal dysmotility, and arthritis, along with an elevated risk of underlying malignancy in adult patients.

Pathophysiologically, it is driven by complement-mediated microangiopathy and robust type I interferon pathway activation, typically accompanied by distinct myositis-specific autoantibodies.

Personalize your experience

Follow Systemic dermatomyositis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it